Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.

Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN.

J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9.

2.

Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses.

Chen WA, Zhang J, Hall KM, Martin CB, Kisselev S, Dasen EJ, Vahanian NN, Link CJ, Martin BK.

PLoS One. 2017 Aug 7;12(8):e0182683. doi: 10.1371/journal.pone.0182683. eCollection 2017.

3.

Effects of isoflavone-containing soya protein on ex vivo cholesterol efflux, vascular function and blood markers of CVD risk in adults with moderately elevated blood pressure: a dose-response randomised controlled trial.

Richter CK, Skulas-Ray AC, Fleming JA, Link CJ, Mukherjea R, Krul ES, Kris-Etherton PM.

Br J Nutr. 2017 May;117(10):1403-1413. doi: 10.1017/S000711451700143X.

4.

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.

Heppner DG Jr, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, Nowak TA, Monath TP; V920-004 study team.

Lancet Infect Dis. 2017 Aug;17(8):854-866. doi: 10.1016/S1473-3099(17)30313-4. Epub 2017 Jun 9.

PMID:
28606591
5.

The Relationship Between Parent Trait Anxiety and Parent-reported Pain, Solicitous Behaviors, and Quality of Life Impairment in Children With Cancer.

Link CJ, Fortier MA.

J Pediatr Hematol Oncol. 2016 Jan;38(1):58-62. doi: 10.1097/MPH.0000000000000376.

PMID:
26056789
6.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

7.

Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

Lai L, Davey R, Beck A, Xu Y, Suffredini AF, Palmore T, Kabbani S, Rogers S, Kobinger G, Alimonti J, Link CJ Jr, Rubinson L, Ströher U, Wolcott M, Dorman W, Uyeki TM, Feldmann H, Lane HC, Mulligan MJ.

JAMA. 2015 Mar 24-31;313(12):1249-55. doi: 10.1001/jama.2015.1995.

8.

Combination immunotherapy for high-risk resected and metastatic melanoma patients.

Riker AI, Rossi GR, Masih P, Alsfeld LC, Denham F, Tennant L, Ramsey WJ, Vahanian NN, Link CJ.

Ochsner J. 2014 Summer;14(2):164-74.

9.

U6 promoter-enhanced GlnUAG suppressor tRNA has higher suppression efficacy and can be stably expressed in 293 cells.

Koukuntla R, Ramsey WJ, Young WB, Link CJ.

J Gene Med. 2013 Feb;15(2):93-101. doi: 10.1002/jgm.2696.

PMID:
23303531
10.

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.

Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC.

Oncoimmunology. 2012 Dec 1;1(9):1460-1468.

11.

Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens.

Hemstreet GP 3rd, Rossi GR, Pisarev VM, Enke CA, Helfner L, Hauke RJ, Tennant L, Ramsey WJ, Vahanian NN, Link CJ.

J Immunother. 2013 Jan;36(1):57-65. doi: 10.1097/CJI.0b013e3182780abc.

PMID:
23211622
12.

Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles.

Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Holbrook MR, Martin BK, Vahanian N, Link CJ, Flick R.

J Virol Methods. 2010 Nov;169(2):259-68. doi: 10.1016/j.jviromet.2010.07.015. Epub 2010 Jul 22.

PMID:
20655330
13.

A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, Holbrook MR, Martin BK, Staplin WR, Vahanian NN, Link CJ, Flick R.

Virology. 2010 Feb 5;397(1):187-98. doi: 10.1016/j.virol.2009.11.001. Epub 2009 Nov 24.

14.

The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade.

Mandell RB, Flick R, Staplin WR, Kaniewski LD, Carzoli AK, Manuszak RP, Wang J, Rossi GR, Vahanian NN, Link CJ.

Zoonoses Public Health. 2009 Aug;56(6-7):391-406. doi: 10.1111/j.1863-2378.2008.01191.x.

PMID:
19486321
15.

Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.

Rossi GR, Mautino MR, Awwad DZ, Husske K, Lejukole H, Koenigsfeld M, Ramsey WJ, Vahanian N, Link CJ.

J Immunother. 2008 Jul-Aug;31(6):545-54. doi: 10.1097/CJI.0b013e31817d2f45.

PMID:
18528300
16.

High-throughput fluorescent screening of transgenic animals: phenotyping and haplotyping.

Hellrung DJ, Rossi G, Link CJ.

Cytometry A. 2006 Oct 1;69(10):1092-5.

17.

Co-expression of alpha(1,3)galactosyltransferase and Bacillus thuringiensis PIPLC enhances hyperacute rejection of tumor cells.

Hellrung DJ, Kisselev S, Link CJ.

Cancer Immunol Immunother. 2007 Jan;56(1):25-34. Epub 2006 Apr 13.

PMID:
16612594
18.

Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes.

Rossi GR, Mautino MR, Unfer RC, Seregina TM, Vahanian N, Link CJ.

Cancer Res. 2005 Nov 15;65(22):10555-61.

19.

Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes.

Rossi GR, Unfer RC, Seregina T, Link CJ.

Cancer Immunol Immunother. 2005 Oct;54(10):999-1009. Epub 2005 May 12.

PMID:
15889257
20.

Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.

Edwin Shackelford R, Manuszak RP, Heard SC, Link CJ, Wang S.

Med Hypotheses. 2005;64(4):736-41.

PMID:
15694690
21.

Iron chelators increase the resistance of Ataxia telangeictasia cells to oxidative stress.

Shackelford RE, Manuszak RP, Johnson CD, Hellrung DJ, Link CJ, Wang S.

DNA Repair (Amst). 2004 Oct 5;3(10):1263-72.

PMID:
15336622
22.

Functional expression of ATM gene carried by HSV amplicon vector in vitro and in vivo.

Qi J, Shackelford R, Manuszak R, Cheng D, Smith M, Link CJ, Wang S.

Gene Ther. 2004 Jan;11(1):25-33.

PMID:
14681694
24.

Desferrioxamine treatment increases the genomic stability of Ataxia-telangiectasia cells.

Shackelford RE, Manuszak RP, Johnson CD, Hellrung DJ, Steele TA, Link CJ, Wang S.

DNA Repair (Amst). 2003 Sep 18;2(9):971-81.

PMID:
12967654
25.

Transduction of hematopoietic stem cells with a retroviral vector expressing the neomycin phosphotransferase gene.

Link CJ, Seregina T, Edleman M, Young WB, Burt RK, Kisselev S.

Bone Marrow Transplant. 2003 Aug;32 Suppl 1:S33-5.

PMID:
12931238
26.

Use of codon-modified, red-shifted variants of green fluorescent protein genes to study virus-mediated gene transfer.

Link CJ Jr, Wang S, Muldoon RR, Seregina T, Levy JP.

Methods Enzymol. 1999;302:424-37. No abstract available.

PMID:
12876790
27.

In vivo retroviral transduction and expression of green fluorescent protein.

Levy JP, Muldoon RR, Mazo IA, Kain SR, Link CJ Jr.

Methods Enzymol. 1999;302:358-69. No abstract available.

PMID:
12876785
28.

Retroviral expression of green fluorescent protein.

Mazo IA, Levy JP, Muldoon RR, Link CJ Jr, Kain SR.

Methods Enzymol. 1999;302:329-41. No abstract available.

PMID:
12876783
30.

Herpes simplex amplicon vectors.

Link CJ, Vahanian NN, Wang S.

Methods Mol Med. 2003;76:61-87. No abstract available.

PMID:
12526159
31.

The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.

Heltemes LM, Hagan CR, Mitrofanova EE, Panchal RG, Guo J, Link CJ.

Cancer Gene Ther. 2003 Jan;10(1):14-22.

PMID:
12489024
33.

Murine retroviral vector producer cells survival and toxicity in the dog liver.

Link CJ Jr, Seregina T, Levy JP, Martin M, Ackermann M, Moorman DW.

In Vivo. 2000 Sep-Oct;14(5):643-9.

PMID:
11212842
34.

Murine retroviral vector producer cells survival and toxicity in the peritoneal cavity of dogs.

Link CJ Jr, Moorman DW, Ackerman M, Levy JP, Seregina T.

In Vivo. 2000 Sep-Oct;14(5):635-41.

PMID:
11212841
35.

Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model.

Turturro F, Heineke HL, Drevyanko TF, Link CJ Jr, Seth P.

Gene Ther. 2000 Jun;7(11):930-3.

36.

Cellular suicide therapy of malignant disease.

Link CJ, Seregina T, Traynor A, Burt RK.

Stem Cells. 2000;18(3):220-6. Review.

37.

Eliciting hyperacute rejection as a tumor killing strategy. Herpes amplicon vector transfer of the alpha(1,3)galactosyltransferase gene.

Link CJ, Hellrung DJ, Seregina T, Wang S.

Adv Exp Med Biol. 2000;465:217-27. Review. No abstract available.

PMID:
10810629
38.

Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene.

Link CJ Jr, Traynor A, Seregina T, Burt RK.

Cancer Treat Res. 1999;101:369-75. Review.

PMID:
10800657
40.

Restriction mapping of retroviral vector episomal DNA.

Young WB, Beecham EJ, Lindberg GL, Link CJ Jr.

Biotechniques. 2000 Mar;28(3):562-5. No abstract available.

41.
42.

Cellular suicide therapy of malignant disease.

Link CJ, Seregina T, Traynor A, Burt RK.

Oncologist. 2000;5(1):68-74. Review.

43.

Direct observation of GFP gene expression transduced with HSV-1/EBV amplicon vector in unfixed tumor tissue.

Qi J, Link CJ Jr, Wang S.

Biotechniques. 2000 Feb;28(2):206-8. No abstract available.

44.

Adenoviral vectors go retro.

Link CJ.

Nat Biotechnol. 2000 Feb;18(2):150-1. No abstract available.

PMID:
10657118
46.

Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes.

Burt RK, Drobyski WR, Traynor AE, Link CJ Jr.

Bone Marrow Transplant. 1999 Nov;24(10):1043-51. Review.

47.

Partial functional correction of xeroderma pigmentosum group A cells by suppressor tRNA.

Panchal RG, Wang S, McDermott J, Link CJ Jr.

Hum Gene Ther. 1999 Sep 1;10(13):2209-19.

PMID:
10498252
48.

DNA vaccination against multiple myeloma.

Stevenson FK, Link CJ Jr, Traynor A, Yu H, Corr M.

Semin Hematol. 1999 Jan;36(1 Suppl 3):38-42. Review.

PMID:
9989489
49.

Radioisotope concentrator gene therapy using the sodium/iodide symporter gene.

Mandell RB, Mandell LZ, Link CJ Jr.

Cancer Res. 1999 Feb 1;59(3):661-8.

50.

Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy.

Link CJ Jr, Seregina T, Atchison R, Hall A, Muldoon R, Levy JP.

Anticancer Res. 1998 Jul-Aug;18(4A):2301-8.

PMID:
9703870

Supplemental Content

Support Center